Akoya's Leading Spatial Proteomics Platforms Selected For Use By UK-Based MANIFEST Consortium To Revolutionize Cancer Immunotherapy
Portfolio Pulse from Benzinga Newsdesk
Akoya Biosciences' spatial proteomics platforms have been selected by the UK-based MANIFEST consortium to advance cancer immunotherapy research. The initiative aims to identify biomarkers predicting treatment success through deep spatial proteomic profiling of cancer tissue samples.
October 07, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akoya Biosciences' spatial proteomics platforms, PhenoCycler® Fusion and PhenoImager® HT, have been selected by the MANIFEST consortium to aid in cancer immunotherapy research. This partnership could enhance Akoya's reputation and demand for its platforms.
The selection of Akoya's platforms by a prestigious consortium for a high-profile research initiative is likely to enhance the company's reputation and increase demand for its products. This could positively impact Akoya's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90